2013-06-04 14:28:38 UTC

Current Celiac Disease Screening Strategy Proves Cost Effective in Preventing Bone Diseases

June 4, 2013

KT Park and colleagues report in Clinical Gastroenterology and Hepatology that universal serologic screening and symptomatic at-risk screening (SAS) are similar in lifetime costs and quality of life, although the current SAS strategy is overall more cost-effective in preventing bone loss and fractures among patients with undiagnosed or subclinical disease.

Patients with asymptomatic or poorly managed celiac disease can experience bone loss, placing them at risk for hip and vertebral fractures. KT Park and colleagues analyzed the cost-effectiveness of universal serologic screening (USS) versus symptomatic at-risk screening (SAS) strategies for celiac disease because of the risk of non-traumatic hip and vertebral fractures if untreated or undiagnosed. They report in Clinical Gastroenterology and Hepatology that USS and SAS are similar in lifetime costs and quality of life, although the current SAS strategy was overall more cost-effective in preventing bone loss and fractures among patients with undiagnosed or subclinical disease. On the basis of best available supportive evidence, it is more cost-effective to maintain the standard celiac screening practices, although future robust population-based evidence in other health outcomes could be leveraged to reevaluate current screening guidelines.

Clinical Gastroenterology and Hepatology 2013: 11(6), 645-653

More on Celiac Disease

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.

APPs: Enhance your delivery of patient care

March 28, 2018

AGA's popular course for advanced practice providers will be held this summer in Chicago.

HLA-DQ–Gluten Tetramer Blood Test Accurately Identifies Patients With and Without Celiac Disease in Absence of Gluten Consumption

March 1, 2018

An HLA-DQ–gluten tetramer based assay that detects gluten-specific T cells accurately identifies patients with and without celiac disease, regardless of whether the individuals are on a gluten-free diet.